| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
85,291 |
78,316 |
$4.75M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
95,734 |
84,991 |
$4.52M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
49,179 |
48,787 |
$2.78M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
15,176 |
15,069 |
$1.01M |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
5,526 |
5,441 |
$293K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
12,127 |
10,817 |
$289K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
3,343 |
3,223 |
$127K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
6,523 |
6,452 |
$35K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,650 |
3,394 |
$32K |
| 93000 |
|
2,149 |
2,109 |
$30K |
| 81002 |
|
5,919 |
5,679 |
$25K |
| 86769 |
|
663 |
652 |
$21K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,658 |
1,584 |
$15K |
| 99070 |
|
4,340 |
3,909 |
$14K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,080 |
1,981 |
$8K |
| 81025 |
|
2,246 |
2,192 |
$8K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,573 |
1,558 |
$7K |
| 99000 |
|
702 |
698 |
$7K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
958 |
938 |
$4K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
797 |
739 |
$4K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
31 |
23 |
$2K |
| 99215 |
Prolong outpt/office vis |
28 |
27 |
$2K |
| 36416 |
|
414 |
407 |
$1K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
27 |
26 |
$997.57 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
16 |
16 |
$820.96 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
95 |
88 |
$760.35 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
156 |
154 |
$670.25 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
16 |
16 |
$657.00 |
| 69209 |
|
195 |
190 |
$537.96 |
| 36415 |
Collection of venous blood by venipuncture |
705 |
687 |
$471.12 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
1,183 |
1,128 |
$440.94 |
| 81000 |
|
29 |
28 |
$411.74 |
| 97602 |
|
60 |
41 |
$296.79 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
131 |
127 |
$237.41 |
| 10060 |
|
14 |
14 |
$236.37 |
| 82962 |
|
86 |
83 |
$127.67 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
27 |
26 |
$119.97 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
452 |
434 |
$77.68 |
| G8783 |
Normal blood pressure reading documented, follow-up not required |
45 |
44 |
$54.08 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
12 |
12 |
$0.35 |